{"version":"1.2.0","chapters":[{"startTime":0,"endTime":375,"title":"Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs)"},{"startTime":375,"endTime":695,"title":"Comparing toxicities of conventional chemotherapy and ADCs"},{"startTime":695,"endTime":910,"title":"Potential of ADCs as maintenance therapy for ovarian cancer"},{"startTime":910,"endTime":1126,"title":"Treatment based on platinum sensitivity and homologous recombination-deficiency status"},{"startTime":1126,"endTime":2482,"title":"Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan"},{"startTime":2482,"endTime":2757,"title":"Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine"},{"startTime":2757,"endTime":3296.261,"title":"Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials"}]}